Global ovarian cancer market expected to generate revenue of around USD 4.01 billion by end of 2024, growing at a CAGR of around 11.82% between 2018 and 2024. Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen.
The report covers the forecast and analysis for the ovarian cancer market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the ovarian cancer market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the ovarian cancer market on a global level.
In order to give the users of this report a comprehensive view of the ovarian cancer market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, where type, cancer stage, diagnostic, treatment, and regional segmentations are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis.
The study provides a decisive view of the ovarian cancer market by segmenting the market based on type, cancer stage, diagnostic, treatment, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024.
The ovarian cancer market is classified based on type, cancer stage, diagnostic, treatment, and region. On the basis of type, the market is divided epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of cancer stage market is segmented as Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market is divided into chemotherapy, targeted therapy, radiation therapy, human chorionic gonadotropin (hCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market is divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery.
The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and The Middle East & Africa with its further bifurcation into major countries including the U.S., Germany, France, U.K., China, Japan, India, and Brazil. This segmentation includes demand for ovarian cancer market based on the individual segment in all the regions and countries.
The report also includes detailed profiles of end players such as Astra Zeneca Plc, Bristol Myers Squibb Company, Genentech Inc., Eli Lilly and Company, Novogen, Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche Ltd., and others.
This report segments the global ovarian cancer market as follows:
Global Ovarian Cancer Market: by Type
Global Ovarian Cancer Market: by Cancer Stage
Global Ovarian Cancer Market: by Diagnostic
Human Chorionic Gonadotropin (hCG) test
Global Ovarian Cancer Market: by Treatment
Global Ovarian Cancer Market: by Region
Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen. These female hormones manage the menstrual cycle along with influencing the development of female body characteristics. In normal conditions, human cells undergo division and fusion that results in the formation of new cells. New cells take the place of old or damaged cells. However, this process is disturbed when cancer develops. In cancer, the old or damaged cells survive and new cells keep appearing. This abnormality could lead to the formation of a tumor, a mass of cells. Ovarian cancer is a disease which involves the abnormal or cancerous growth of the cells in the ovaries. There are four major types of ovarian cancer: Epithelial ovarian cancer, Borderline tumors, Germ cell ovarian cancer, and Sex-cord stromal cell cancer. The cancer types are determined based on the location of the ovarian cells where the cancerous growth starts. After starting from ovaries, ovarian cancer spreads to the pelvis and abdomen region. Ovarian cancer is virtually undetectable when it is in the ovaries.
According to World Cancer Research Fund International, ovarian cancer comes in at the eighteenth number on the list of most common cancer and on the seventh number in the list of common cancer in women. The highest occurrence of ovarian cancer is found in North America and Europe. As per the estimates are given by American Cancer Society for the year 2018, in the United States around 22,400 women are expected to receive ovarian cancer diagnosis and around 14,070 ovarian cancer deaths will occur. Ovarian cancer causes more deaths than any other female reproductive system cancers. Ovarian cancer is the fifth leading cause of death due to cancer in women. About 1 in 78 women are at the risk of getting ovarian cancer. Women in the age group of 50 to 60 years are at a higher risk of getting ovarian cancer.
The strongest risk factors that can cause ovarian cancer are acquired genetic changes, genetic mutations called BRCA1 or BRCA2, old age, obesity, not having a full-term pregnancy, using fertility treatment, hormone therapy post menopause, and PTEN tumor hamartoma syndrome.
Factors such as increasing geriatric population of women rise in ovarian cancer cases, availability of new drugs and therapies, increase in healthcare expenditure, and increased government funding are expected to boost the growth of ovarian cancer market. However, availability of generic drugs and patent expiration of branded drugs can act as a restraint in the growth of the ovarian cancer market. The lack of precise diagnostic techniques for ovarian cancer in the early stages can also have a negative impact on the global ovarian cancer market.
On the basis of the type the ovarian cancer market has been divided into epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of the cancer stage, the market is segmented into Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market divided into the physical examination, biopsy, blood tests, Human Chorionic Gonadotropin (HCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. In the forecast period, the diagnostic segment will dominate the global market as ovarian cancer is most chemosensitive cancer.
North America will be the dominant region during the forecast period. Increasing prevalence of ovarian cancer in the region and availability of latest diagnostic methods are the factors that will boost the ovarian cancer market in this region. Europe will be the second largest market. The Asia Pacific will grow at the fastest rate over the forecast period. Increasing healthcare expenditure and growing attention towards ovarian cancer diagnosis are the driving factors for the growth of the ovarian cancer market in this region. Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa are expected to experience noticeable growth in the years to come.
Some of the key players in ovarian cancer market include Astra Zeneca Plc, Bristol Myers Squibb Company, Genentech Inc., Eli Lilly and Company, Novogen, Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche Ltd., and others.
Request the coronavirus impact analysis across industries and markets